Designer steroids - over-the-counter supplements and their androgenic component: Review of an increasing problem

Andrology

Volumn 3, Issue 2, 2015, Pages 150-155

  Rahnema, C D ^a   Crosnoe, L E ^a   Kim, E D ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

Anabolic steroid induced hypogonadism; Designer steroids; Dietary supplements; Dimethazine; Mentabolan; Methylstenbolone

Indexed keywords

DIMETHAZINE; MENTABOLAN; METHOXYGONADIENE; METHYLCLOSTEBOL; METHYLEPITIOSTANOL; METHYLSTENBOLONE; STEROID; UNCLASSIFIED DRUG; ANABOLIC AGENT; ANDROGEN; DESIGNER DRUG; NON PRESCRIPTION DRUG;

CHOLESTASIS; DIET SUPPLEMENTATION; GYNECOMASTIA; HEALTH HAZARD; HUMAN; HYPOGONADISM; INFERTILITY; KIDNEY FAILURE; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; FEMALE; MALE;

ANABOLIC AGENTS; ANDROGENS; DESIGNER DRUGS; FEMALE; HUMANS; MALE; NONPRESCRIPTION DRUGS;

EID: 84928287895     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/andr.307     Document Type: Review

References (40)

1. Bagatell CJ & Bremner WJ. (1996) Androgens in men - uses and abuses. N Engl J Med 334, 707-714.
2. Baume N, Mahler N, Kamber M, Mangin P & Saugy M. (2006) Research of stimulants and anabolic steroids in dietary supplements. Scand J Med Sci Sports 16, 41-48.
3. Brennan BP, Kanayama G & Pope HG Jr. (2013) Performance-enhancing drugs on the web: a growing public-health issue. Am J Addict 22, 158-161.
4. Buzby GC Jr, Walk CR, Smith H. (1966) Totally synthetic steroid hormones. X. Some (plus or minus)-13beta-ethyl-7alpha-methylgonane derivatives. J Med Chem 9, 782-784.
5. Campbell JA, Lyster SC, Duncan GW & Babcock JC. (1963) 7α-Methyl-18-norsteroids: a new class of potent anabolic and androgenic hormones. Steroids 1, 317-324.
6. Cavalcanti G. de A, Leal FD, Garrido BC, Padilha MC & de Aquino Neto FR. (2013) Detection of designer steroid methylstenbolone in "nutritional supplement" using gas chromatography and tandem mass spectrometry: elucidation of its urinary metabolites. Steroids 78, 228-233.
7. Cohen PA. (2012) Assessing supplement safety - the FDA's controversial proposal. N Engl J Med 366, 389-391.
8. Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW & Lipshultz LI. (2013) Anabolic steroid-induced hypogonadism in young men. J Urol 190, 2200-2205.
9. Criminal Investigations (2011) Dietary Supplements Manufacturer Sentenced, n.d. Available at: http://www.fda.gov/ICECI/CriminalInvestigations/ucm254526.htm.
10. De Ruggieri P, Matscher R, Gandolfi C, Chiaramonti D, Lupo C, Pietra E & Cavalli R. (1963) A new steroid having proteo-anabolic action: dimethazine. Arch Sci Biol (Bologna) 47, 1-19.
11. Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schänzer W, Thevis M, Vollmer G & Zierau O. (2007) Characterisation of the pharmacological profile of desoxymethyltestosterone (Madol), a steroid misused for doping. Toxicol Lett 169, 64-71.
12. Drug Enforcement Administration (DEA), Department of Justice (2009) Classification of three steroids as schedule III anabolic steroids under the Controlled Substances Act. Final rule. Fed Regist 74, 63603-63610.
13. Edgren RA, Peterson DL, Jones RC, Nagra CL, Smith H & Hughes GA. (1966) Biological effects of synthetic gonanes. Recent Prog Horm Res 22, 305-349.
14. FDA Law Blog: Designer Anabolic Steroid Control Act of 2012 Introduced; Would Bulk Up Federal Anabolic Steroid Controls, n.d. Available at: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2012/07/designer-anabolic-steroid-control-act-of-2012-introduced-would-bulk-up-federal-anabolic-steroid-cont.html.
15. FDA Warns Manufacturers About Illegal Steroid Products Sold as Dietary Supplements. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108613.htm.
16. Geldof L, Lootens L, Polet M, Eichner D, Campbell T, Nair V, Botrè F, Meuleman P, Leroux-Roels G, Deventer K & Eenoo PV. (2014) Metabolism of methylstenbolone studied with human liver microsomes and the uPA(+/+) -SCID chimeric mouse model. Biomed Chromatogr 28, 974-985.
17. Geyer H, Parr MK, Koehler K, Mareck U, Schänzer W & Thevis M. (2008) Nutritional supplements cross-contaminated and faked with doping substances. J Mass Spectrom 43, 892-902.
18. Hughes GA & Smith H. (1976) Synthesis of 13-Alkyl-Gon-4-Ones. US3959322 A.
19. Kanayama G, Gruber AJ, Pope HG Jr, Borowiecki JJ & Hudson JI. (2001) Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem?. Psychother Psychosom 70, 137-140.
20. Kanayama G, Brower KJ, Wood RI, Hudson JI & Pope HG Jr. (2009) Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 104, 1966-1978.
21. Kazlauskas R. (2010) Designer steroids. Handb Exp Pharmacol 195, 155-185.
22. Konishi Y, Morimoto T, Komaki K, Yamakawa T, Mituyama N, Tanaka T, Oomine Y & Monden Y. (1988) A case of advanced breast cancer successfully treated with combined tamoxifen and epitiostanol. Gan To Kagaku Ryoho 15, 2163-2167.
23. Kurachi K, Aono T, Tomoyama J, Matsumoto K & Nakasima A. (1975) Effects of 2alpha, 3alpha-epithio-5alpha-androstan-17beta-ol (epitiostanol) on hypothalamo-pituitary-gonadal axis in humans. Acta Obstet Gynaecol Jpn 22, 42-48.
24. Lootens L, Meuleman P, Leroux-Roels G & Van Eenoo P. (2011) Metabolic studies with promagnon, methylclostebol and methasterone in the uPA+/+-SCID chimeric mice. J Steroid Biochem Mol Biol 127, 374-381.
25. Matscher R, Lupo C & De Ruggieri P. (1962) Biological activity of dimethazine in the protein anabolic sense. Boll Soc Ital Biol Sper 38, 988-990.
26. Nasr J & Ahmad J. (2009) Severe cholestasis and renal failure associated with the use of the designer steroid Superdrol (methasteron): a case report and literature review. Dig Dis Sci 54, 1144-1146.
27. Nieschlag E, Kumar N & Sitruk-Ware R. (2013) 7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism. Contraception 87, 288-295.
28. Nutting EF, Klimstra PD & Counsell RE. (1966) Anabolic-androgenic activity of A-ring modified androstane derivatives. Acta Endocrinol (Copenh) 53, 627-634.
29. Okano M, Sato M, Ikekita A & Kageyama S. (2009) Analysis of non-ketoic steroids 17alpha-methylepithiostanol and desoxymethyl- testosterone in dietary supplements. Drug Test Anal 1, 518-525.
30. Press Announcements - FDA Warns Consumers About Health Risks With Healthy Life Chemistry Dietary Supplement, n.d. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362799.htm.
31. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR & Kim ED. (2014) Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 101(5), 1271-1279.
32. Sagoe D, Molde H, Andreassen CS, Torsheim T & Pallesen S. (2014) The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 24(5), 383-398.
33. Segaloff A. (1963) The enhanced local androgenic activity of 19-nor steroids and stabilization of their structure by 7α- and 17α-methyl substituents to highly potent androgens by any route of administration. Steroids 1, 299-315.
34. Shah NL, Zacharias I, Khettry U, Afdhal N & Gordon FD. (2008) Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol 6, 255-258.
35. Shamloul RM, Aborayah AF, Hashad A & Abd-Allah F. (2014) Anabolic steroids abuse-induced cardiomyopathy and ischaemic stroke in a young male patient. BMJ Case Rep 26, 1582-1589.
36. Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, Williams JE, Balan V, Douglas DD & Rakela J. (2009) Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J Clin Gastroenterol 43, 287.
37. Ueda H, Hagino Y, Ono M & Kuwano M. (1986) Human mammary cancer cell mutants with altered hormone receptor activity. J Biochem 100, 341-348.
38. Van Thuyne W, Van Eenoo P & Delbeke FT. (2006) Nutritional supplements: prevalence of use and contamination with doping agents. Nutr Res Rev 19, 147-158.
39. Vida JA. (1969) Androgens and Anabolic Agents. Chemistry and Pharmacology. Academic Press, New York.
40. World Anti-Doping Program (2013) The 2014 Prohibited List International Standard. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf.